PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment
Wing Lam, Zaoli Jiang, Fulan Guan, Xiu Huang, Rong Hu, Jing Wang, Scott Bussom, Shwu-Huey Liu, Hongyu Zhao, Yun Yen, Yung-Chi Cheng, Wing Lam, Zaoli Jiang, Fulan Guan, Xiu Huang, Rong Hu, Jing Wang, Scott Bussom, Shwu-Huey Liu, Hongyu Zhao, Yun Yen, Yung-Chi Cheng
Abstract
PHY906 (KD018) is a four-herb Chinese Medicine Formula. It has been shown to potentially enhance the therapeutic indices of different class anticancer agents in vivo. Here, PHY906 is reported to enhance the anti-tumor activity of Sorafenib in nude mice bearing HepG2 xenografts. Among the four herbal ingredients of PHY906, Scutellaria baicalensis Georgi (S) and Paeonia lactiflora Pall (P) are required; however, S plays a more important role than P in increasing tumor apoptosis induced by Sorafenib with an increase of mouse(m)FasL and human(h)FasR expression. PHY906 may potentiate Sorafenib action by increasing hMCP1 expression and enhancing infiltration of macrophages into tumors with a higher M1/M2 (tumor rejection) signature expression pattern, as well as affect autophagy by increasing AMPKα-P and ULK1-S555-P of tumors. Depletion of macrophage could counteract PHY906 to potentiate the anti-tumor activity of Sorafenib. It was reported that tumor cells with higher levels of ERK1/2-P are more susceptible to Sorafenib, and the S component of PHY906 may increase ERK1/2-P via inhibition of ERK1/2 phosphatase in HepG2 tumors. PHY906 may potentiate the anti-hepatoma activity of Sorafenib by multiple mechanisms targeting on the inflammatory state of microenvironment of tumor tissue through two major ingredients (P and S) of PHY906.
Conflict of interest statement
Yung-Chi Cheng and Shwu-Huey Liu are the co-inventors of PHY906 for cancer treatment.
Figures
References
- El-Serag H. B. Hepatocellular carcinoma. N Engl J Med 365, 1118–1127 (2011).
- Llovet J. M. & Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48, 1312–1327 (2008).
- Wilhelm S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64, 7099–7109 (2004).
- Llovet J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359, 378–390 (2008).
- Tilton R. et al. A comprehensive platform for quality control of botanical drugs (PhytomicsQC): a case study of Huangqin Tang (HQT) and PHY906. Chinese medicine 5, 30 (2010).
- Lam W. et al. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Science translational medicine 2, 45ra59 (2010).
- Rockwell S. et al. Preclinical studies of the Chinese Herbal Medicine formulation PHY906 (KD018) as a potential adjunct to radiation therapy. International journal of radiation biology 89, 16–25 (2013).
- Wang E. et al. Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment. BMC medical genomics 4, 38 (2011).
- Farrell M. P. & Kummar S. Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer 2, 253–256 (2003).
- Kummar S. et al. A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer 10, 85–96 (2011).
- Saif M. W. et al. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. Phytomedicine 17, 161–169 (2010).
- Saif M. W. et al. First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 73, 373–380 (2013).
- Yen Y. et al. Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. Anticancer research 29, 4083–4092 (2009).
- Talmadge J. E., Donkor M. & Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer metastasis reviews 26, 373–400 (2007).
- Shang L. et al. Nutrient starvation elicits an acute autophagic response mediated by Ulk1 dephosphorylation and its subsequent dissociation from AMPK. Proc Natl Acad Sci U S A 108, 4788–4793 (2011).
- Egan D. F. et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331, 456–461 (2011).
- Abou-Alfa G. K. et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24, 4293–4300 (2006).
- Zhang Z., Zhou X., Shen H., Wang D. & Wang Y. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC medicine 7, 41 (2009).
- Liu S. H. & Cheng Y. C. Old formula, new Rx: the journey of PHY906 as cancer adjuvant therapy. Journal of ethnopharmacology 140, 614–623 (2012).
- Park M. A. et al. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Molecular cancer therapeutics 9, 2220–2231 (2010).
- Walker T. et al. Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Mol Pharmacol 76, 342–355 (2009).
- Zhang W. et al. Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS). Journal of chromatography. A 1217, 5785–5793 (2010).
- Boya P., Reggiori F. & Codogno P. Emerging regulation and functions of autophagy. Nat Cell Biol 15, 713–720 (2013).
- Loos B., Engelbrecht A. M., Lockshin R. A., Klionsky D. J. & Zakeri Z. The variability of autophagy and cell death susceptibility: Unanswered questions. Autophagy 9 (2013).
- Tai W. T. et al. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. Cell death & disease 4, e485 (2013).
- Patterson K. I., Brummer T., O'Brien P. M. & Daly R. J. Dual-specificity phosphatases: critical regulators with diverse cellular targets. The Biochemical journal 418, 475–489 (2009).
- Cagnol S. & Chambard J. C. ERK and cell death: mechanisms of ERK-induced cell death--apoptosis, autophagy and senescence. The FEBS journal 277, 2–21 (2010).
- Tewari R., Sharma V., Koul N. & Sen E. Involvement of miltefosine-mediated ERK activation in glioma cell apoptosis through Fas regulation. Journal of neurochemistry 107, 616–627 (2008).
- Goillot E. et al. Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. Proc Natl Acad Sci U S A 94, 3302–3307 (1997).
- Cagnol S., Van Obberghen-Schilling E. & Chambard J. C. Prolonged activation of ERK1,2 induces FADD-independent caspase 8 activation and cell death. Apoptosis: an international journal on programmed cell death 11, 337–346 (2006).
- Cheng Y., Qiu F., Tashiro S., Onodera S. & Ikejima T. ERK and JNK mediate TNFalpha-induced p53 activation in apoptotic and autophagic L929 cell death. Biochemical and biophysical research communications 376, 483–488 (2008).
- An H. J. et al. Activation of Ras up-regulates pro-apoptotic BNIP3 in nitric oxide-induced cell death. The Journal of biological chemistry 281, 33939–33948 (2006).
- Ogier-Denis E., Pattingre S., El Benna J. & Codogno P. Erk1/2-dependent phosphorylation of Galpha-interacting protein stimulates its GTPase accelerating activity and autophagy in human colon cancer cells. The Journal of biological chemistry 275, 39090–39095 (2000).
Source: PubMed